Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
Aggarwal, C. et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181 (2023).
Google ScholarÂ
Gandara, D. R. et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J. Immunother. Cancer 13, e010311 (2025).
Kazama, A. et al. Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. Sci. Rep. 12, 20386 (2022).
Google ScholarÂ
Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2004).
Google ScholarÂ
Kimura, T. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. 6, 18–26 (2013).
Google ScholarÂ
Schoen, R. E. et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin. Cancer Res. 29, 1678–1688 (2023).
Google ScholarÂ
Vonderheide, R. H. Cancer vaccines are back, revitalized. Med. 4, 395–397 (2023).
Google ScholarÂ
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363, 411–422 (2010).
Google ScholarÂ
Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
Google ScholarÂ
Shiller J. T. et al. Cancer vaccines. Cancer Cell 40. 559–564 (2022).
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Google ScholarÂ
Vici, P. et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev. Vaccines 15, 1327–1336 (2016).
Google ScholarÂ
Rice, A. E. et al. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 22, 454–462 (2015).
Google ScholarÂ
Bartkowiak, T. et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc. Natl. Acad. Sci. USA 112, E5290–E5299 (2015).
Google ScholarÂ
Vici, P. et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J. Exp. Clin. Cancer Res. 33, 29 (2014).
Google ScholarÂ
Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351 (2016).
Google ScholarÂ
Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).
Google ScholarÂ
Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 56 (2019).
Google ScholarÂ
Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375–382 (2019).
Google ScholarÂ
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
Google ScholarÂ
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Google ScholarÂ
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
Google ScholarÂ
Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752 (2013).
Google ScholarÂ
van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013).
Google ScholarÂ
Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. New Engl. J. Med. 375, 2255–2262 (2016).
Google ScholarÂ
Turcotte, S. et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin. Cancer Res. 20, 331–343 (2014).
Google ScholarÂ
Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81–85 (2015).
Google ScholarÂ
Deffrennes, V. et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167, 98–106 (2001).
Google ScholarÂ
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
Google ScholarÂ
Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209–2223 (2024).
Google ScholarÂ
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
Google ScholarÂ
Merck/Moderna. Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection (NCT3897881). https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/ (2026).
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Google ScholarÂ
Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).
Google ScholarÂ
Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362 (2020).
Google ScholarÂ
Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188, 5125–5141 (2025).
Mork, S. K. et al. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF(R)09b, in patients with metastatic melanoma. Oncoimmunology 11, 2023255 (2022).
Google ScholarÂ
Mork, S. K. et al. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. J. Immunother. Cancer 12, e008817 (2024).
Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).
Google ScholarÂ
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
Google ScholarÂ
Gerber, H. P., Sibener, L. V., Lee, L. J. & Gee, M. Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochem. Pharmacol. 168, 275–284 (2019).
Google ScholarÂ
Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).
Google ScholarÂ
Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474–482 (2025).
Google ScholarÂ
Quintanilha, J. C. F. et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis. Oncol. 7, e2300092 (2023).
Google ScholarÂ
Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4, 418–428 (2018).
Google ScholarÂ
Conn, B. P. et al. Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Rep. Methods 5, 101049 (2025).
Google ScholarÂ
Wainberg, Z. A. et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat. Med. 31, 3648–3653 (2025).
Google ScholarÂ
Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).
Google ScholarÂ
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
Google ScholarÂ
Bhadury, J., Lopez, M. D., Muralidharan, S. V., Nilsson, L. M. & Nilsson, J. A. Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis 2, e44 (2013).
Google ScholarÂ
Efremova, M. et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat. Commun. 9, 32 (2018).
Google ScholarÂ
Kinkead, H. L. et al. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight 3, e122857 (2018).
Huff, A. L. et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight 8, e174027 (2023).
Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639, 1042–1051 (2025).
Google ScholarÂ
Park, W., Chawla, A. & O’Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851–862 (2021).
Google ScholarÂ
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. New Engl. J. Med. 360, 765–773 (2009).
Google ScholarÂ
Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463–468 (2021).
Google ScholarÂ
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
Google ScholarÂ
Sipos, D. et al. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers 17, 146 (2025).
Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010–1026 (2022).
Google ScholarÂ
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
Google ScholarÂ
Latzer, P. et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat. Commun. 15, 6870 (2024).
Google ScholarÂ
Garfinkle, E. et al. Perales-Linares, R., Gimple, R., Yan, J. & Navarro, J. CTIM-33. Personalized multivalent DNA vaccination safely induces broad neoantigen-specific T cell responses in newly diagnosed MGMT unmethylated glioblastoma in a clinically relevant time scale. In Proc. SNO Annual Meeting Vol. 27 (Oxford University Press, 2025).
Zagzag, D. et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab. Investig. 85, 328–341 (2005).
Google ScholarÂ
Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235–251 (2023).
Google ScholarÂ
Zhang, X. et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 16, 131 (2024).
Google ScholarÂ
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
Google ScholarÂ
Gao, H., Yang, J. & Li, Y. Triple-negative breast cancer survival outcomes: prognostic model validated with SEER database. Discov. Oncol. 17, 258 (2026).
Google ScholarÂ
Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat. Med. 30, 1044–1053 (2024).
Google ScholarÂ
Zhao, B., Zhao, H. & Zhao, J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 12, 1758835920937612 (2020).
Google ScholarÂ
Saxena, M. et al. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematologic malignancies in the adjuvant setting. Cancer Discov. 15, 930–947 (2025).
Google ScholarÂ
Schaeffeler, E., Walz, J. & Schwab, M. Personalized cancer vaccination is emerging: lessons learnt from renal cancer and challenges for broader application. Signal Transduct. Target. Ther. 10, 107 (2025).
Google ScholarÂ
Ely, Z. A. et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025).
Google ScholarÂ
Sultan, H. & Schreiber, R. D. Cancer neoantigen vaccines emerge efficacious. Annu. Rev. Med. 77, 297–314 (2026).
Google ScholarÂ
Esprit, A. et al. Neo-antigen mRNA vaccines. Vaccines 8, 776 (2020).
Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213–227 (2024).
Google ScholarÂ
Gfeller, D., Racle, J., Harari, A. & Croce, G. Advances in predicting T cell epitope recognition for cancer immunotherapy. Nat. Cancer 7, 711–722 (2026).
Zhang, Y. et al. Advances and challenges in neoantigen prediction for cancer immunotherapy. Front. Immunol. 16, 1617654 (2025).
Google ScholarÂ
Janowitz, T., Kleeman, S. & Vonderheide, R. H. Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy. Oncologist 26, 269–273 (2021).
Google ScholarÂ
Polyakov, L. et al. Impact of glucocorticoids on immune checkpoint inhibitor efficacy and circulating biomarkers in non-small cell lung cancer patients. Cancer Res. Commun. 5, 1082–1094 (2025).
Google ScholarÂ
Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).
Google ScholarÂ
Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Investig. 130, 5976–5988 (2020).
Google ScholarÂ
Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231–1243 (2019).
Google ScholarÂ
Sahin, U. et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature 651, 1088–1096 (2026).
Google ScholarÂ
Salvatori, E. et al. Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. NPJ Vaccines 7, 15 (2022).
Google ScholarÂ
Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022).
Google ScholarÂ
Gowda, P., Govindu, S. R. & Hsiehchen, D. Impact of tumor burden on immune checkpoint and conventional therapy responses and outcomes. Cancer Res. Commun. 5, 1978–1983 (2025).
Google ScholarÂ
Tarantino, P. et al. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur. J. Cancer 139, 92–98 (2020).
Google ScholarÂ
Secli, L. et al. Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model. J. Immunother. Cancer 13, e013035 (2025).
Jo, S. et al. mRNA vaccines engage unconventional pathways in CD8(+) T cell priming. Nature 654, 485–494 (2026).
Marks, A. et al. mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. Nat. Biotechnol. 1–15 https://doi.org/10.1038/s41587-026-03099-z (2026).
Rastogi, I., Muralidhar, A. & McNeel, D. G. Vaccines as treatments for prostate cancer. Nat. Rev. Urol. 20, 544–559 (2023).
Google ScholarÂ
Finn, O. J. et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61–89 (1995).
Google ScholarÂ
Hofmann, O. et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl. Acad. Sci. USA 105, 20422–20427 (2008).
Google ScholarÂ
Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).
Google ScholarÂ
Bakker, A. B. et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005–1009 (1994).
Google ScholarÂ
Halder, S. et al. Targeting the EGFR signaling pathway in cancer therapy: what’s new in 2023? Expert Opin. Ther. Targets 27, 305–324 (2023).
Google ScholarÂ
Uribe, M. L., Marrocco, I. & Yarden, Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers 13, 2748 (2021).
Akincilar, S. C., Chan, C. H. T., Ng, Q. F., Fidan, K. & Tergaonkar, V. Non-canonical roles of canonical telomere binding proteins in cancers. Cell Mol. Life Sci. 78, 4235–4257 (2021).
Google ScholarÂ
Vonderheide, R. H. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov. Med. 7, 103–108 (2007).
Google ScholarÂ
Saraiya, M. et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J. Natl. Cancer Inst. 107, djv086 (2015).
Google ScholarÂ
Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770–2788 (2022).
Google ScholarÂ
Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231–2248 (2014).
Google ScholarÂ
Rech, A. J. et al. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol. Res. 6, 276–287 (2018).
Google ScholarÂ
Borden, E. S., Buetow, K. H., Wilson, M. A. & Hastings, K. T. Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation. Front. Oncol. 12, 836821 (2022).
Google ScholarÂ
Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2018).
Google ScholarÂ
Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112–121 (2023).
Google ScholarÂ
Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013–1022 (2024).
Google ScholarÂ
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Google ScholarÂ
Sharma, P., Hoorn, D., Aitha, A., Breier, D. & Peer, D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv. Drug Deliv. Rev. 205, 115175 (2024).
Google ScholarÂ
Han, F. et al. Microorganism delivery of cancer vaccines. J. Control Release 388, 114288 (2025).
Google ScholarÂ
Jung, D. et al. CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination. J. Control Release 396, 115053 (2026).
